Skip to main content
Log in

Correction for Non-Ideal Tracer Pharmacokinetic Disposition by Disposition Decomposition Analysis (DDA)

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Pharmacokinetic (PK) studies assume that the tracer's PK is equivalent to the parent compound. This assumption is often violated. The aim of this work is to present a method enabling the ideal tracer PK, i.e. the PK of the parent compound, to be predicted from the non-ideal tracer.

Methods. The procedure uses a disposition decomposition-recomposition (DDR) that assumes that the labeling mainly changes the elimination kinetics while the distribution kinetics is not significantly affected. In the DDR procedure an elimination rate constant correction factor (kCOR) is determined from a simultaneously fitting to plasma concentration data resulting from an i.v. injection of both the tracer and the parent compound. The correction factor is subsequently used to predict the ideal tracer PK behavior from the disposition function (i.v. bolus response) of the non ideal tracer.

Results. The DDR method when applied to plasma level data of erythropoietin (r-HuEPO) and its iodinated tracer (l25I-r-HuEPO) from a high (4000U/kg) and a low (400U/kg) dosing of r-HuEPO in newborn lambs (n = 13) resulted in excellent agreements in the elimination rate corrected dispositions in all cases (r = 0.995, SD = 0.0095). The correction factor did not show a dose dependence (p > 0.05). The correction factors were all larger than 1 (kCOR = 1.94, SD = 0.519) consistent with a reduction in the EPO elimination by the iodination labeling.

Conclusions. The DDR tracer correction methodology produces a better differentiation of the PK of endogenously produced compounds by correcting for the non-ideal PK behavior of chemically produced tracers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. J. B. Bauer, S. D. Leigh, C. A. Birr, S. L. Bernhard, M. Fang, K. Der, N. O. Ihejeto, S. F. Carroll, and A. H. Kung. Alteration of the pharmacokinetics of small proteins by iodination. Biopharm. Drug Disp. 17:761–774 (1996).

    Google Scholar 

  2. J. A. Widness, R. L. Schmidt, P. Veng-Pedersen, N. B. Modi, and S. T. Sawyer. A sensitive and specific erythropoietin immunoprecipitation assay: Application to pharmacokinetic studies. J. Lab. Clin. Med. 119:285–294 (1992).

    PubMed  Google Scholar 

  3. J. A. Widness, P. Veng-Pedersen, N. B. Modi, R. L. Schmidt, and D. H. Chestnut.: Developmental differences in crythropoietin pharmacokinetics: Increased clearance and distribution in fetal and neonatal sheep. J. Pharmacol. Exp. Therap, 261: 977–984 (1992).

    Google Scholar 

  4. P. Veng-Pedersen. Drug absorption evaluation in the presence of changes in clearance: An algorithm and computer program for deconvolution with exact clearance correction. J. Pharmacokin. Biopharm., 8:185–203 (1987).

    Google Scholar 

  5. W. R. Gillespie and P. Veng-Pedersen. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions II. Clearance concepts applied to the evaluation of distribution kinetics. J. Pharmacokin. Biopharm., 13:441–451 (1985).

    Google Scholar 

  6. P. Veng-Pedersen and W. R. Gillespie. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics, J. Pharmacokin. Biopharm. 15:281–304 (1987).

    Google Scholar 

  7. H. Cheng, Y. Gang, and W. J. Jusko. A computer program for calculating distribution parameters for drugs behaving nonlinearly that is based on disposition decomposition analysis, J. Pharm. Sci., 83: 110–112 (1994).

    PubMed  Google Scholar 

  8. P. Veng-Pedersen. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT, J. Pharmacokin. Biopharm., 5:513–520 (1977).

    Google Scholar 

  9. W. Jelkmann. Erythropoietin: Structure, control of production, and function. Physiol. Rev. 72:449–489 (1992).

    PubMed  Google Scholar 

  10. S. T. Sawyer, S. B. Krantz, et al. Binding and receptor-mediated endocytosis of erythropoietin and friend virus-infected erythroid cells. J Biol Chem 262:5554–5562 (1987).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Veng-Pedersen, P., Hong, S.S., Widness, J.A. et al. Correction for Non-Ideal Tracer Pharmacokinetic Disposition by Disposition Decomposition Analysis (DDA). Pharm Res 15, 1469–1473 (1998). https://doi.org/10.1023/A:1011922209757

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011922209757

Navigation